Related Experiment Video

Updated: Aug 24, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Associations between inflammatory markers and myocardial injury in patients treated with pitavastatin : A

Yifan Mao1, Wei Zhou2

  • 1School of Clinical Medicine, Guizhou Medical University, No. 9, Beijing Road, Yunyan District, Guiyang 550004, Guizhou Province, China.

Pakistan Journal of Pharmaceutical Sciences
|August 22, 2026
PubMed

Insights

In patients treated with pitavastatin, elevated inflammatory markers like hs-CRP, IL-6, and TNF-α are linked to myocardial injury. Monitoring these markers can help improve patient prognosis and cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Biochemistry
  • Clinical Medicine

Background:

  • Inflammation is a key driver of atherosclerosis and myocardial injury.
  • Research on pitavastatin's impact on inflammation and myocardial injury markers is limited.

Purpose of the Study:

  • To investigate the correlation between inflammatory marker levels and myocardial injury indices in patients receiving pitavastatin.
  • To identify independent risk factors for myocardial injury in this patient cohort.

Main Methods:

  • Retrospective study of 100 pitavastatin-treated patients, stratified into myocardial injury and non-myocardial injury groups.
  • Assessed inflammatory markers (hs-CRP, IL-6, TNF-α, MCP-1, FIB) and myocardial injury indices (cTnI, CK-MB, LDH, Mb).
  • Employed Spearman's correlation and logistic regression analyses to determine relationships and risk factors.

Main Results:

  • Patients with myocardial injury exhibited significantly higher levels of inflammatory markers and myocardial injury indices compared to the non-injury group.
  • Elevated hs-CRP, IL-6, and TNF-α were identified as independent risk factors for myocardial injury.
  • A positive correlation was observed between inflammatory markers and myocardial injury indices.

Conclusions:

  • Inflammatory markers are significantly correlated with myocardial injury in patients undergoing pitavastatin treatment.
  • Monitoring hs-CRP, IL-6, and TNF-α levels can aid in predicting and managing myocardial injury.
  • These findings suggest potential therapeutic targets for improving cardiovascular outcomes in pitavastatin-treated patients.
Abstract

Keywords:
CorrelationInflammatory markersMyocardial injuryPitavastatin

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...